-+ 0.00%
-+ 0.00%
-+ 0.00%

Can-Fite Biopharma Completes Treatment Of First 247 Patients In Its Phase III Study Evaluating Piclidenoson For Moderate-To-Severe Plaque Psoriasis; Expects Results Of Pre-Specified Interim Analysis In Q1 2027

Benzinga·11/18/2026 12:07:06
Listen to the news

The company announced that the last patient in the interim-analysis cohort of its pivotal Phase III psoriasis study received the final dose of study treatment. Results of the pre-specified interim analysis are expected to be read out by the Independent Data Monitoring Committee (IDMC) in Q1 2027.

Completion of dosing marks a key milestone toward the interim analysis, which will evaluate the efficacy and safety of Piclidenoson in patients with moderate-to-severe plaque psoriasis. The Company previously announced completion of enrolment of the first 247 patients for this analysis.

Piclidenoson is an investigational, orally administered A3 adenosine receptor agonist that targets inflammatory pathways implicated in psoriasis. Its clinical development program includes a safety database involving more than 1,500 subjects. If successfully developed and approved, Piclidenoson could offer a unique oral treatment option for patients requiring long-term management of their disease, with a favorable safety profile that supports chronically administered.

The randomized, double-blind, placebo-controlled study is being conducted under a protocol agreed with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Patients receive Piclidenoson 3 mg or placebo orally twice daily. The co-primary efficacy endpoints at Week 16 are the proportion of patients achieving at least a 75% improvement in the Psoriasis Area and Severity Index (PASI 75) and the proportion achieving a static Physician’s Global Assessment (sPGA) score of 0 or 1, corresponding to clear or almost clear skin.